Incyte Corporation (INCY)vsInsmed Inc (INSM)
INCY
Incyte Corporation
$92.23
+1.78%
HEALTHCARE · Cap: $18.03B
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Incyte Corporation generates 748% more annual revenue ($5.14B vs $606.42M). INCY leads profitability with a 25.0% profit margin vs -2.1%. INCY appears more attractively valued with a PEG of 0.32. INCY earns a higher WallStSmart Score of 83/100 (A-).
INCY
Exceptional Buy83
out of 100
Grade: A-
INSM
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+67.0%
Fair Value
$299.99
Current Price
$92.23
$207.76 discount
Intrinsic value data unavailable for INSM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Safe zone — low bankruptcy risk
Every $100 of equity generates 30 in profit
Keeps 25 of every $100 in revenue as profit
Attractively priced relative to earnings
Strong operational efficiency at 25.6%
No standout strengths identified
Areas to Watch
No major concerns identified
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : INCY
The strongest argument for INCY centers on PEG Ratio, Altman Z-Score, Return on Equity. Profitability is solid with margins at 25.0% and operating margin at 25.6%. Revenue growth of 27.8% demonstrates continued momentum.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : INCY
No major red flags identified for INCY, but monitor valuation.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
INCY profiles as a growth stock while INSM is a turnaround play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INCY is growing revenue faster at 27.8% — sustainability is the question.
INCY generates stronger free cash flow (521M), providing more financial flexibility.
Bottom Line
INCY scores higher overall (83/100 vs 39/100), backed by strong 25.0% margins and 27.8% revenue growth. Both earn "Exceptional Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Incyte Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?